Frank L. Urbano, MD

I want to respond to the negative experience that Al Lewis details in his March 2014 Viewpoint “My Own Trip Into the Treatment Trap … A Cautionary Tale” ( While I agree with some of his comments, I feel that he oversimplifies the issues, doesn’t consider the physician’s viewpoint, and makes statements that are offensive in their tone and assumptions.

Lewis details how he developed symptoms, went to an ENT specialist and then was prescribed several courses of action. He then proceeds to dissect them and detail why they were incorrect, and essentially how this physician was completely wrong in how she approached his problem. He says that she “subliminally marketed” a surgical correction to his problem without first considering conservative treatment options, and that this is because she makes more money by doing surgery. Isn’t it equally plausible that in her experience with problems like his (which far outweighs Lewis’s experience, which is why he went to her in the first place), surgery might have been a better option?

Doesn’t this physician deserve the benefit of the doubt in this case, that she might actually be interested in Lewis’s welfare and not her pocketbook?

Next, Lewis criticizes the physician for not describing “the drawbacks or risks of taking a course of antibiotics.” I agree that if she omitted this information, she was not fully informing her patient; however, perhaps the physician didn’t go into the information because so many other patients simply demand antibiotics without reference to their potential toxicities, and when she was seeing Lewis, she thought he might act the same way. Besides, if he was truly concerned about the potential toxicities of three weeks of antibiotics, why didn’t he ask for more information? The physician-patient relationship is a two-way street.

Lewis comments on how “doctors are supposed to follow evidence-based guidelines,” but what about conditions for which there are none? And is there no patient individuality or leeway in this process? Lewis’s statement is an oversimplification of how a physician manages a patient’s problem; if we are only to follow guidelines, then why are we needed at all? Why just not punch your symptoms into a computer and then have it spit out a treatment based upon “evidence-based guidelines”?

Other entities

As to Lewis’s comments about the physician scheduling a CT scan the next week, I admire his self-concern about not being exposed to the ionizing radiation associated with a CT scan; however, how does he know that the reason for the CT scan was only to monitor the progress of his treatment (which he didn’t even want to take)? Isn’t it possible that the physician wanted to look for other entities that might be causing his symptoms, or see areas of his anatomy that were beyond the reach of her “gadget”? And later on in the article when he comments about physician-owned equipment, is he referring to this physician’s ownership of a CT scanner as the reason why she recommended the scan in the first place? That is nowhere to be found in the article.

Now, I do actually agree with some of what Lewis says, particularly that there is a need for payment reform in health care, and we do need to move from volume to value in how we pay physicians and organizations for health care. I also agree that there are some physicians who put personal enrichment ahead of patient well-being, but in my opinion, this is a very small minority. Unfortunately, the tone of Lewis’s article makes one believe that the world is filled with greedy physicians who just want to order more tests and get paid more for things that really aren’t necessary — and I submit that this couldn’t be further from the truth. There are many other factors that drive a physician’s practice to do more “doctor-type stuff,” and Lewis’s article mentions none of them, which leads to his lopsided analysis.

Lewis says, “My take-away from this experience was that doctors do doctor-type stuff because they’re doctors, and unless you literally take away any payment involved in doing more, they will continue to do what they are trained to do.” This is an incredibly offensive oversimplification that makes physicians sound like trained seals and in no way reflects how physicians practice in today’s world. If I were to rewrite this statement to be accurate, I would say that “doctors take care of patients in the best way they know how to do, and when they do more doctor-type stuff, it is either because patients demand it, or because they believe patients truly need it. In both instances, the physicians are doing what they feel is the best thing for the patient at the time they are seeing them.”

I’d like to ask Lewis how he would have felt if the physician he went to see had examined him and then said, “You have nasal polyps and you don’t have to do anything about them.” Would he have been satisfied with that response? Would he have believed that response or would he have sought another opinion? I would submit to Lewis and others that physicians sometimes recommend actions because that’s what’s expected of them, and when they don’t, patients wonder why they went to the physician in the first place; so, because physicians are human, they try to do what they think is best for the patient, and that may be ordering a test or prescribing a treatment. In the future, we will need to change the way we pay for health care. And since physicians drive a lot of those costs, they are easy targets for criticism like that spewed forth by Lewis. But I would submit that before you criticize physicians for driving costs up, you look in the mirror and see what part others have to play in this drama. After all, if Lewis hadn’t visited the physician in the first place, he wouldn’t have had a story to write about.

Physicians aren’t the bumbling, money-hungry charlatans that Lewis makes them appear to be. They are simply one of many players in a dysfunctional system that needs to be fixed.

Frank L. Urbano, MD, is the medical director for care management at Einstein Healthcare Network in Philadelphia.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.